Variations of ganglioside biosynthetic pathways in the phenotype conversion from myofibroblasts to lipocytes in murine hepatic stellate cell line
- PMID: 17440688
- DOI: 10.1007/s11010-007-9464-z
Variations of ganglioside biosynthetic pathways in the phenotype conversion from myofibroblasts to lipocytes in murine hepatic stellate cell line
Abstract
GRX cell line represents hepatic stellate cell and can be transformed from an actively proliferation myofibroblast phenotype into a quiescent fat-storing lipocyte phenotype. Both express the same gangliosides (GM3, GM2, GM1 and GD1a), which are resolved as doublets on HPTLC. Upper/lower band ratio is increased in lipocyte-like cells and the upper band is composed by ceramides with long-chain fatty acids. This study evaluated the contribution of de novo synthesis, sphingosine and Golgi recycling pathways on ganglioside biosynthesis, in both phenotypes. Cells were preincubated with 5 mM beta-chloroalanine (SPT: serine palmitoyltransferase inhibitor) or with 25 muM fumonisin B1 (ceramide synthase inhibitor) and then radiolabeled with [U-(14)C]galactose in the continued presence of inhibitors. Gangliosides were extracted, purified and analyzed by HPTLC. In myofibroblast-like cells, simple gangliosides use the de novo pathway while complex gangliosides are mainly synthesized by recycling pathways. In lipocyte-like cells, de novo pathway has a lesser contribution and this is in agreement with the lower activity of the committed enzyme of sphingolipid synthesis (SPT) detected in this phenotype. SPT mRNA has an identical expression in both phenotypes. It was also observed that gangliosides doublets from myofibroblast-like cells have the same distribution between triton soluble and insoluble fractions (upper band > lower band) while the gangliosides doublets from lipocyte-like cells show an inversion in the insoluble fraction (lower band > upper band) in comparison to soluble fraction. These results indicate that myofibroblast- and lipocyte-like cells have important differences between the glycosphingolipid biosynthetic pathways, which could contribute with the respective glycosphingolipid-enriched membrane microdomain's composition.
Similar articles
-
Changes of sphingolipid species in the phenotype conversion from myofibroblasts to lipocytes in hepatic stellate cells.J Cell Biochem. 2003 Feb 15;88(3):533-44. doi: 10.1002/jcb.10373. J Cell Biochem. 2003. PMID: 12532329
-
Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ.J Biol Chem. 1993 Dec 25;268(36):27299-306. J Biol Chem. 1993. PMID: 8262970
-
Cell type specific localization of sphingomyelin biosynthesis.FEBS Lett. 2000 Jul 28;478(1-2):9-12. doi: 10.1016/s0014-5793(00)01818-4. FEBS Lett. 2000. PMID: 10922460
-
Ganglioside/glycosphingolipid turnover: new concepts.Glycoconj J. 2004;20(5):301-17. doi: 10.1023/B:GLYC.0000033627.02765.cc. Glycoconj J. 2004. PMID: 15229395 Review.
-
Sphingolipid synthetic pathways are major regulators of lipid homeostasis.Adv Exp Med Biol. 2011;721:139-48. doi: 10.1007/978-1-4614-0650-1_9. Adv Exp Med Biol. 2011. PMID: 21910087 Review.
Cited by
-
Resveratrol inhibits cell growth by inducing cell cycle arrest in activated hepatic stellate cells.Mol Cell Biochem. 2008 Aug;315(1-2):1-7. doi: 10.1007/s11010-008-9781-x. Epub 2008 May 4. Mol Cell Biochem. 2008. PMID: 18454344
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources